ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Is Amyloid Binding Alcohol Dehydrogenase a Drug Target for Treating Alzheimer's Disease?
dc.contributor.author | Borger, Eva | |
dc.contributor.author | Aitken, Laura | |
dc.contributor.author | Du, Heng | |
dc.contributor.author | Zhang, Wenshen | |
dc.contributor.author | Gunn-Moore, Frank J. | |
dc.contributor.author | Yan, Shirley ShiDu | |
dc.date.accessioned | 2017-02-27T22:23:46Z | |
dc.date.available | 2017-02-27T22:23:46Z | |
dc.date.issued | 2014-01-01 | |
dc.identifier.citation | Borger, Eva, Laura Aitken, Heng Du, Wenshen Zhang, Frank J. Gunn-Moore, and Shirley Shi Du Yan. "Is Amyloid Binding Alcohol Dehydrogenase a Drug Target for Treating Alzheimer's Disease?" Current Alzheimer Research 10.1 (2013): 21-29. | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23279 | |
dc.description.abstract | Current strategies for the treatment of Alzheimer's disease (AD) involve tackling the formation or clearance of the amyloid-beta peptide (Aβ) and/or hyper-phosphorylated tau, or the support and stabilization of the remaining neuronal networks. However, as we gain a clearer idea of the large number of molecular mechanisms at work in this disease, it is becoming clearer that the treatment of AD should take a combined approach of dealing with several aspects of the pathology. The concept that we also need to protect specific sensitive targets within the cell should also be considered. In particular the role of protecting the function of a specific mitochondrial protein, amyloid binding alcohol dehydrogenase (ABAD), will be the focus of this review. Mitochondrial dysfunction is a well-recognized fact in the progression of AD, though until recently the mechanisms involved could only be loosely labeled as changes in `metabolism'. The discovery that Aβ can be present within the mitochondria and specifically bind to ABAD, has opened up a new area of AD research. Here we review the evidence that the prevention of Aβ binding to ABAD is a drug target for the treatment of AD. | en_US |
dc.publisher | Bentham Science Publishers | en_US |
dc.subject | ABAD | en_US |
dc.subject | Mitochondria | en_US |
dc.subject | Alzheimer's disease | en_US |
dc.subject | Drug discovery | en_US |
dc.title | Is Amyloid Binding Alcohol Dehydrogenase a Drug Target for Treating Alzheimer's Disease? | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Yan, Shirley Shidu | |
kusw.kudepartment | Pharmacology & Toxicology | en_US |
dc.identifier.doi | 10.2174/1567205011310010004 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
-
Pharmacy Scholarly Works [299]